Navigation Links
Vaccine Boosts Survival for Men With Advanced Prostate Cancer: Study
Date:7/28/2010

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, July 28 (HealthDay News) -- A newly approved therapeutic prostate cancer vaccine extended the lives of men with metastatic tumors resistant to standard hormonal treatment, a new study shows.

The vaccine, called Provenge (sipuleucel-T), improved survival by about four months compared with no treatment and involved less toxicity than chemotherapy. However, with a round of treatment potentially costing $93,000, the therapy could be out of the financial reach of many patients.

"The strategy of trying to harness the immune system to fight cancer has been something that people have tried to attain for many years; this is one such strategy," said lead researcher Dr. Philip Kantoff, a professor of medicine at Harvard Medical School and a medical oncologist at the Dana-Farber Cancer Institute in Boston.

One expert said the therapy, while far from a cure, "looks promising." Dr. Elizabeth Kavaler, an urologist at Lenox Hill Hospital in New York City, said that, "in this unfortunate category of [hormone-resistant] patient, we have very little to offer. Adding months to a man's life is better than doing nothing, especially if the treatment involves minimal morbidity, as this vaccine promises."

The new study, funded by the vaccine's maker, Dendreon, is published in the July 29 issue of the New England Journal of Medicine.

Provenge is a therapeutic (not preventive) vaccine made from the patient's own white blood cells. Once removed from the patient, the cells are treated with the drug and placed back into the patient. These treated cells then trigger an immune response that in turn kills cancer cells, leaving normal cells unharmed. Provenge is given intravenously in a three-dose schedule delivered in two-week intervals.

In April, the U.S. Food and Drug Administration approved Provenge for treatment of prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment.

For the study, Kantoff's group randomly assigned 512 men to receive Provenge or placebo. All of patients had advanced prostate cancer that had proven resistant to standard hormonal therapy.

On average, men receiving Provenge lived 4.1 months longer than men receiving placebo, the researchers found. Average survival was 25.8 months for men in the Provenge group, compared with 21.7 months for men in the placebo group, meaning that Provenge extended survival by 22 to 25 percent, Kantoff said.

He contends that if the vaccine was used by men with less severe disease survival, it might be extended for even longer.

"Theoretically, if you take people with less diseases and you stimulate the immune system, you could have a more profound effect, but we don't really know that yet," he said.

Compared with other treatments, such as chemotherapy, radiation and hormone therapy, Provenge has been touted as having fewer and less severe side effects. In this trial, the most common side effects were chills, fever and headache, the researchers noted.

Kantoff said the vaccine is just the first step in immune system therapies for cancer. "This study opens the door for a whole new form of therapy, which is immunotherapy," Kantoff said.

Another vaccine for prostate cancer, called GVAX, had been tested in a phase 3 trial, Kantoff noted, "but that didn't work."

"There are many other things that could work and they are in development right now. The hope is there will be many things that will work. This study is really a proof of principle that the concept works and hopefully there will be many other things that will add to, or improve upon this," he said.

Prostate cancer expert Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, said that "the concept of immunotherapy for prostate cancer was unexpected, but important and perhaps the beginning of a new approach to the treatment of this disease."

He added, "The only thing that doesn't make it a home run is you are not curing anybody, but you are prolonging their life and their quality of life with a treatment that has very little toxicity."

However, the availability and cost of Provenge are issues that need to be resolved, D'Amico said. "It's very expensive and there is going to be a huge demand for it."

A four-week treatment with Provenge would cost as much as $93,000, according to an editorial accompanying the study.

Moreover, new guidelines are expected to recommend the use of Provenge before using the new chemotherapy drug Taxotere (docetaxel), D'Amico said. "Taxotere, although less expensive, has a lot more toxicity and has about the same benefits [as Provenge]," he said.

Commenting on the high cost of Provenge, Kantoff countered that "this is a treatment given over a four-week period, as opposed to other treatments that are given over many months, where the costs can be high as well, if not comparable to or more expensive [than Provenge]."

More information

For more information on prostate cancer, visit the American Cancer Society.

SOURCES: Philip Kantoff, M.D., professor, medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, Boston; Elizabeth Kavaler, M.D., urologist, Lenox Hill Hospital, New York City; Anthony D'Amico, M.D., Ph.D., chief, radiation oncology, Brigham and Women's Hospital, Boston; July 29, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Vaccine May Prevent TB in People With HIV
2. Vaccine Not Fail-Safe in Ongoing Mumps Outbreak
3. New strategy produces promising advance in cancer vaccines
4. Screens, Vaccine for HPV Less Beneficial in Older Women
5. New Technology Could Widen Reach of Vaccines
6. Texas-based consortium announces groundbreaking vaccine research program
7. The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies Failure to Provide Adequate Safety Research
8. Possible vaccine for mesothelioma proven safe
9. Groundbreaking research to find vaccine for hepatitis C
10. Vaccine for Asbestos-Related Cancer Looks Safe
11. CDC Awards Abt Associates Additional Contracts to Evaluate Effectiveness of H1N1 Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vaccine Boosts Survival for Men With Advanced Prostate Cancer: Study
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
Breaking Medicine Technology: